Targeted therapy for relapsed B-cell leukemia and lymphoma using CAR T-cells
Official title: Iomab-ACT: A phase I/II study of 131-I apamistamab targeted lymphodepletion followed by CD19-targeted CAR T-cell therapy for patients with relapsed or refractory B-ALL or DLBCL
Funded at Actinium Pharmaceuticals, INC. · NIH-10892773 · Data updated 2026-11-12
This study is testing a new treatment for adults with tough-to-treat B-cell leukemia and lymphoma, using special CAR T-cells along with a unique method to help make the treatment safer and more effective.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Actinium Pharmaceuticals, INC. NIH-funded |
| Lab location | 1 site (New York, UNITED STATES) |
| Project start | September 9, 2020 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $865,308 |
| NIH project number | 5R42CA254685-03 |
| Project ID | NIH-10892773 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults aged 21 and older who have relapsed or refractory B-ALL or DLBCL.
✕Less likely to help
Patients with other types of cancers or those who are not relapsed or refractory may not benefit from this research.
What this research studies
This research investigates a new treatment approach for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL). It combines a targeted therapy using CD19-directed CAR T-cells with a novel conditioning treatment that aims to reduce side effects while enhancing the effectiveness of the CAR T-cell therapy. The study focuses on using a specific antibody labeled with iodine to deplete certain immune cells before administering the CAR T-cells, potentially improving patient outcomes. Patients will be monitored for both efficacy and safety throughout the treatment process.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for patients with difficult-to-treat B-cell malignancies.
How similar studies have gone: Previous research has shown promising results with CAR T-cell therapies, but this specific approach using targeted lymphodepletion is novel.
Where this research is happening
-
Actinium Pharmaceuticals, INC.
New York, United States Active
Researchers
- Principal investigator: Desai, Avinash — Actinium Pharmaceuticals, INC.
- Study coordinator: Desai, Avinash
Related research
Other NIH-funded projects on the same topics.
-
Improving CAR T-cell therapy for pediatric B-ALL
A physician-scientist at St. Jude aims to advance CAR T-cell therapy for children with high-risk B-ALL by testing new donor-derived and enhanced autologous CAR T-cell approaches in early-phase trials.
-
Enhancing CART-T therapy for B-cell lymphoma with longer-lasting IL-7/IL-15/IL-21 support
This grant tests a new treatment approach that combines CAR-T cells for large B-cell lymphoma with a long-acting growth factor cocktail to help the CAR-T cells expand and persist.
-
Improving CAR T-cell therapy for children with leukemia
This study is looking at a new kind of CAR T-cell therapy for kids with B-cell Acute Lymphoblastic Leukemia (B-ALL) to see if using special donor cells can make the treatment safer and more effective, while also helping the cells stay in the body longer to keep the cancer from coming back.
-
SynthNode: A new, easier way to make CAR T cells for better cancer treatment
A new implantable device called SynthNode could simplify and lower the cost of CAR T cell therapy, helping patients with lymphoma, myeloma, and potentially solid tumors or lupus.
-
Preventing childhood B-ALL through maternal diet and TVA intake
A study at Loyola University Chicago will explore whether a mother’s intake of TVA during pregnancy can help prevent childhood B-ALL in babies.
-
Intraperitoneal CAR T cells for peritoneal mesothelioma
A new approach uses CAR T cells delivered directly into the abdominal cavity to target mesothelioma, aiming to help people whose disease is confined to the abdomen.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.